Effects Of 17β-oestradiol On Pathomechanism Of Osteoblasts With Myeloma Cells

PartⅠDetection of Serum Osteoprotegerin in Patients with Multiple Myeloma and Its Clinical SignificanceObjective Osteoprotegerin was an important factor of development and progression in multiple myeloma bone disease. The study was aimed to investigate the serum osteoprotegerin levels in patients with multiple myeloma and relationship with bone disease and prognosis.Methods The levels of serum osteoprotegerin were detected in 28 patients with multiple myeloma and 28 controls by ELISA.Results OPG was lower in the patients with multiple myeloma [(222.4±114.8) pg/ml] than controls. OPG levels in patients with 0-1 bone lesions were (312.4±129.6) pg/ml, patients with 2-3 bone lesions were (179.0±59.4) pg/ml, This difference was statistically significant (P<0.01). Osteprotegerin levels were associated withβ2-microglobulin and globulin levels (P<0.01), associated with albumin levels possibly (P=0.696), and not concerned with stage immunologic type, hemoglobin and calcium levels.Conclusion Serum osteoprotegerin levels were reduced in patients with multiple myeloma levels, and associated with degree of skeletal destruction. Importantly, OPG may be used for estimating prognosis of patients with multiple myeloma. PartⅡEffects of 17β-oestradiol on pathomechanism of osteoblasts with myeloma cellsObjective The study was aimed to investigate effects of E2 on proliferation function and gene expression of osteoblasts which treated by myeloma cells, and searched for its effects on multiple myeloma bone disease.Methods Primary osteoblasts were cultured at DMEM which include 20% control media, and treated by E2. Proliferation was detected by MTT after 24 hours, ALP activity was detected after 48 hours, mineralization was detected after 14 days. Osteoblasts were cocultured with myeloma cells and treated by E2, the expressions of RANKL and OPG were assayed by RT-PCR, and secretions were assayed by ELISA.Results In the bone marrow environment with myeloma cells, proliferation and function of osteoblasts were inhibited, the expression and secretion of RANKL was enhanced and OPG was depressed. 10-5～10-8mol/L E2 could promote the proliferation and ALP activity of osteoblasts which were inhibited by MM cells, and in a dose-dependent manner. 10-6～10-8mol/L E2 could promote mineralization. In coculture experiments, E2 could inhibit the expression and secretion of RANKL, promote the expression and secretion of OPG.Conclusion In the bone marrow microenvironment with myeloma cells, E2 promoted the proliferation and function of osteoblasts. Moreover, E2 inhibited the activity of osteoclasts though RANKL and OPG. So, E2 could be an effective medicine possiblly.